Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto J Montero

Showing results (51-60 of 132) with videos related to

Pageof 14
Sort By:
Gastrointestinal Cancer Research : GCR|March 5, 2009
Optimizing imatinib mesylate treatment in gastrointestinal stromal tumorsYixing Jiang, Lee Ming, Alberto J Montero, et al.
The Journal of Surgical Research|January 19, 2023
Adjuvant Therapy in Breast Cancer Patients With Microscopic Residual DiseaseLifen Cao, Robert Shenk, Nickolas Stabellini, et al.
Cancer|April 1, 2022
A comparison of local therapy alone with local plus systemic therapy for stage I pT1aN0M0 HER2+ breast cancer: A National Cancer Database analysisLifen Cao, Christopher W Towe, Robert Shenk, et al.
Frontiers in Oncology|May 11, 2023
Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysisNickolas Stabellini, Lifen Cao, Christopher W Towe, et al.
Current Problems in Cancer|July 10, 2026
Genomic risk distribution, adjuvant chemotherapy trends, and survival outcomes in women with pT1, grade 1-2, ER/PR-positive, LVI-negative breast cancerNickolas Stabellini, Maya Lubarsky, Ananya Munjal, et al.
Breast Cancer Research and Treatment|October 16, 2021
Adjuvant trastuzumab with or without chemotherapy in stage 1 pT1N0 HER2+ breast cancer: a National Cancer Database analysisLifen Cao, Robert Shenk, Nickolas Stabellini, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Debating the Optimal Approach to Nodal Management After Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast CancerStacey Carter, Heather Neuman, Eleftherios P Mamounas, et al.
Journal of Gastrointestinal Oncology|July 20, 2012
Patient with synchronous low grade leiomyosarcoma of the thigh, primary pancreatic neuroendocrine tumor, and lung metastases: Why biopsy of metastases should be the standardJesus Fabregas, Tony N Talebi, Caio Rocha Lima, et al.
Current Medical Research and Opinion|November 8, 2016
Comparison of health utility weights among elderly patients receiving breast-conserving surgery plus hormonal therapy with or without radiotherapyAskal Ayalew Ali, Hong Xiao, Rima Tawk, et al.
Breast Cancer Research and Treatment|July 12, 2014
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancerVakaramoko Diaby, Georges Adunlin, Simon B Zeichner, et al.
Pageof 14

Showing results (51-60 of 132) with videos related to

Sort By:
Pageof 14
Gastrointestinal Cancer Research : GCR|March 5, 2009
Optimizing imatinib mesylate treatment in gastrointestinal stromal tumorsYixing Jiang, Lee Ming, Alberto J Montero, et al.
The Journal of Surgical Research|January 19, 2023
Adjuvant Therapy in Breast Cancer Patients With Microscopic Residual DiseaseLifen Cao, Robert Shenk, Nickolas Stabellini, et al.
Cancer|April 1, 2022
A comparison of local therapy alone with local plus systemic therapy for stage I pT1aN0M0 HER2+ breast cancer: A National Cancer Database analysisLifen Cao, Christopher W Towe, Robert Shenk, et al.
Frontiers in Oncology|May 11, 2023
Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysisNickolas Stabellini, Lifen Cao, Christopher W Towe, et al.
Current Problems in Cancer|July 10, 2026
Genomic risk distribution, adjuvant chemotherapy trends, and survival outcomes in women with pT1, grade 1-2, ER/PR-positive, LVI-negative breast cancerNickolas Stabellini, Maya Lubarsky, Ananya Munjal, et al.
Breast Cancer Research and Treatment|October 16, 2021
Adjuvant trastuzumab with or without chemotherapy in stage 1 pT1N0 HER2+ breast cancer: a National Cancer Database analysisLifen Cao, Robert Shenk, Nickolas Stabellini, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Debating the Optimal Approach to Nodal Management After Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast CancerStacey Carter, Heather Neuman, Eleftherios P Mamounas, et al.
Journal of Gastrointestinal Oncology|July 20, 2012
Patient with synchronous low grade leiomyosarcoma of the thigh, primary pancreatic neuroendocrine tumor, and lung metastases: Why biopsy of metastases should be the standardJesus Fabregas, Tony N Talebi, Caio Rocha Lima, et al.
Current Medical Research and Opinion|November 8, 2016
Comparison of health utility weights among elderly patients receiving breast-conserving surgery plus hormonal therapy with or without radiotherapyAskal Ayalew Ali, Hong Xiao, Rima Tawk, et al.
Breast Cancer Research and Treatment|July 12, 2014
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancerVakaramoko Diaby, Georges Adunlin, Simon B Zeichner, et al.
Pageof 14